BridgeBio Oncology Therapeutics, Inc (BBOT) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: BBOT has a “Moderate Buy” consensus, with 10 buy ratings and one sell rating. The average 12-month price target is $21.11, although several firms recently lowered their targets.
• The stock has declined sharply: BBOT opened at $2.62, near its 12-month low of $2.51 and well below its 12-month high of $14.87. Its 50-day and 200-day moving averages are $5.00 and $8.13, respectively.
• The company remains deeply unprofitable: BridgeBio Oncology Therapeutics reported quarterly EPS of negative $705.20, while analysts expect a full-year loss of $2.81 per share. Institutional investors own approximately 54.89% of the stock.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) has received an average rating of "Moderate Buy" from the eleven analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $21.11.

BBOT has been the topic of a number of recent research reports. Morgan Stanley dropped their price objective on shares of BridgeBio Oncology Therapeutics to $13.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 21st. Leerink Partners reduced their price target on shares of BridgeBio Oncology Therapeutics to $27.00 and set an "outperform" rating for the company in a research report on Thursday, September 10th. Oppenheimer dropped their price objective on BridgeBio Oncology Therapeutics to $16.00 and set an "outperform" rating for the company in a research note on Tuesday, October 20th. Wall Street Zen raised BridgeBio Oncology Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, October 17th. Finally, Stifel Nicolaus cut their price objective on BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a research report on Wednesday, September 9th.

BridgeBio Oncology Therapeutics Stock Performance

NASDAQ:BBOT opened at $2.62 on Monday. The company has a market capitalization of $210.05 million, a P/E ratio of -0.95 and a beta of 0.86. BridgeBio Oncology Therapeutics has a 12 month low of $2.51 and a 12 month high of $14.87. The firm has a fifty day simple moving average of $5.00 and a 200-day simple moving average of $8.13.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. Equities analysts forecast that BridgeBio Oncology Therapeutics will post -2.81 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BBOT. Tidal Investments LLC grew its holdings in shares of BridgeBio Oncology Therapeutics by 13.6% during the 2nd quarter. Tidal Investments LLC now owns 93,339 shares of the company's stock valued at $711,000 after purchasing an additional 11,167 shares during the last quarter. Tema ETFs LLC lifted its position in shares of BridgeBio Oncology Therapeutics by 13.6% during the second quarter. Tema ETFs LLC now owns 93,339 shares of the company's stock valued at $711,000 after buying an additional 11,167 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in BridgeBio Oncology Therapeutics during the 3rd quarter worth about $63,000. Renaissance Technologies LLC boosted its stake in BridgeBio Oncology Therapeutics by 37.1% during the 1st quarter. Renaissance Technologies LLC now owns 101,900 shares of the company's stock worth $912,000 after purchasing an additional 27,600 shares during the last quarter. Finally, Avidity Partners Management LP acquired a new stake in BridgeBio Oncology Therapeutics in the 1st quarter valued at approximately $392,000. Institutional investors own 54.89% of the company's stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with genetically driven cancers. The company is part of the broader BridgeBio platform, which supports the development of therapies for diseases linked to well-defined biological targets.

Its oncology programs are centered on small-molecule therapies intended to address cancer-causing genetic alterations, including targets that have historically been difficult to treat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.